Nexcelom Bioscience is a pioneer in the field of cell counting and cell-based assays since 2003. We work with cell therapy researchers to ensure Precision, Linearity, Accuracy, and Reproducibility of data. In this interview, Dr. Jean Qiu, our founder, and CTO, describes 3 major reasons why we partner with global and local research organizations to streamline CAR T workflow.
Request a Demo
CAR T Brochure

The CAR T Cell Revolution

Cancer immunotherapy has been revolutionized by the discovery and development of chimeric antigen receptors (CAR) T cells. CAR T cells are defined as genetically engineered allogeneic T cells that are isolated from blood, developed in the laboratory using viral vectors, and then infused into a patient to fight cancer cells. CAR T cell therapy is type of immunotherapy that has already received two FDA approvals for tisagenlecleucel (Kymriah) from Novartis and Axicabtagene ciloleucel (Yescarta) from Kite Pharma/Gilead. Researchers will soon break ground on how to use CARs for solid tumors.

Accurate Cell Counting Matters

A common thread that unifies researchers and regulators is the importance of immune cell quality in the CAR-T workflow. Ensuring accurate and consistent cell counts, viability, and functionality (e.g. CAR-T cytotoxicity) is why most premier research organizations choose Nexcelom cell counters and image cytometers.